Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?

Bisphosphonates have demonstrated anti-tumour activity in preclinical studies of bone metastatic disease, thus it was natural to transition these agents into the adjuvant cancer therapy setting. Surprisingly, the results of adjuvant breast cancer trials have shown either modest to no benefit or even...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Kent, Clemons, Mark, Costa, Luis, Addison, Christina L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723323/
https://www.ncbi.nlm.nih.gov/pubmed/26909249
http://dx.doi.org/10.1016/j.jbo.2012.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723323/
https://www.ncbi.nlm.nih.gov/pubmed/26909249
http://dx.doi.org/10.1016/j.jbo.2012.04.003

Ejemplares similares